<div id="readability-page-1"><div><p>(MT Newswires) -- Nanjing Vazyme Biotech (SHA:688105) obtained medical device registration certificates in China for seven diagnostic reagent kits focused on neurological diseases.</p><p> The newly approved products include biomarkers for Alzheimer's disease and Parkinson's disease, according to a Thursday filing with the Shanghai bourse.</p><p>The certificates are valid until Sept. 22, 2030.</p></div></div>

诺唯赞

<p>（MT Newswires）-- 南京诺唯赞生物科技（SHA:688105）获得了中国针对神经系统疾病的七种诊断试剂盒的医疗器械注册证书。根据周四向上海证券交易所提交的文件，新批准的产品包括阿尔茨海默病和帕金森病的生物标志物。这些证书有效期至 2030 年 9 月 22 日</p>

南京诺唯赞生物科技公司获得了关键神经疾病检测试剂盒的监管批准